Histamine H3 Receptor Antagonists Go to Clinics
Kerstin Sander, Tim Kottke, Holger Stark · Biological and Pharmaceutical Bulletin · 2008
Within the recent years novel lead optimisations for histamine H(3) receptor antagonists made their way from bench to bedside. Structure-activity relationships, cross-affinities and side effects as well as pharmacokinetic profiling will be discussed on selected promising compound series. Due to diversity in potential therapeutic applications and in some cases a controversial debate, different indications will be highlighted with the potential and the problems of the test compounds, e.g. sleep-wake disorders, attention-deficient hyperactivity disorder, epilepsy, cognitive impairment, schizophrenia, obesity and neuropathic pain. First data published on clinical trials phase II (IIb) are presented showing proof of concept of H(3) receptor antagonists in narcolepsy and photo-induced epilepsy.
Cited by 193 works. doi:10.1248/bpb.31.2163 Open-access PDF
Authors
References
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1
- Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis
- Narcolepsy in orexin Knockout Mice
- The Sleep Disorder Canine Narcolepsy Is Caused by a Mutation in the Hypocretin (Orexin) Receptor 2 Gene
- SOMNOLENCE CAUSED BY HYPOTHALAMIC LESIONS IN THE MONKEY
- Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor
- COMPARATIVE ASSAYS OF ANTIEPILEPTIC DRUGS IN MICE AND RATS
- HYPOTHALAMIC REGULATION OF SLEEP IN RATS. AN EXPERIMENTAL STUDY
- Highly potent and selective ligands for histamine H3-receptors
- The glamour and gloom of glycogen synthase kinase-3